Inhibikase Therapeutics, Inc. IKT R2KPHARMA
Company Overview
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -7.02% |
| 6 Months: | -15.43% |
| 3 Months: | -32.34% |
| 1 Month: | -24.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.10 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 36.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IKT Inhibikase Therapeutics, Inc. R2KPHARMA | 1.59 | -3.61 | $221.86M | 0.00% | -30.85% | -51.96% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 270.79K | 219.59K | 37.68K | 1.41M | 1.36M | 328.46K | 46.03K | 6.55K | 7.29K | 64.52K | 116.41K | 79.57K | 0 | 0 | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.76M | 11.19M | 13.26M | 13.13M | 18.22M |
| Operating Income | -540.01K | -413.92K | -663.71K | -2.63M | -2.63M | -4.47M | -4.64M | -4.64M | -4.51M | -4.71M | -6.20M | -4.77M | -4.78M | -5.05M | - | - | -15.76M | -11.19M | -13.26M | -13.13M | -18.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.75M | -11.17M | -13.24M | -13.13M | -18.22M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.68M | -9.92M | -11.93M | -12.73M | -16.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -547.44K | -421.87K | -670.60K | -2.64M | -2.64M | -4.47M | -4.64M | -4.64M | -4.49M | -4.48M | -5.78M | -4.60M | -4.65M | -4.96M | - | - | -13.68M | -9.92M | -11.93M | -12.73M | -16.38M |
| Diluted EPS | - | - | - | - | -0.22 | -0.18 | -0.18 | -1.10 | -1.06 | -0.98 | -1.11 | -0.86 | -0.73 | -0.66 | -0.65 | - | -0.15 | -0.11 | -0.13 | - | -0.10 |
| R&D Expense | 283.11K | 263.18K | 120.57K | 2.43M | 2.38M | 3.15M | 3.02M | 2.98M | 2.98M | 2.85M | 4.54M | 3.23M | 2.75M | 3.08M | 4.19M | - | 10.51M | 5.27M | 7.65M | - | 10.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 698.47K | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 18.13M | 20.09M | 28.59M | 53.35M |
| Operating Income | -2.82M | - | -18.13M | -20.09M | -28.59M | -53.35M |
| EBITDA | - | - | -18.12M | -19.91M | -28.56M | -53.29M |
| Interest Expense | - | 19.92K | - | - | - | - |
| Pretax Income | - | - | -18.05M | -19.03M | -27.52M | -48.26M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -2.85M | - | -18.05M | -19.03M | -27.52M | -48.26M |
| Diluted EPS | - | - | -4.28 | -3.16 | -1.16 | -0.49 |
| R&D Expense | 893.80K | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 14.78M | 42.47M | 24.94M | 14.51M | 98.60M | 181.20M |
| Total Equity | -4.49M | 9.78M | 38.42M | 21.04M | 10.98M | 94.87M | 172.90M |
| Cash & Equivalents | - | - | 40.75M | 7.19M | 9.20M | 97.50M | 178.80M |
| Long Term Debt | - | - | 248.91K | - | 381.78K | - | - |
| Total Liabilities | - | 5.00M | 4.05M | 3.90M | 3.53M | 3.73M | 8.30M |
| Current Liabilities | - | 4.72M | 4.05M | 3.70M | 3.44M | 3.73M | 8.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.13M | -14.30M | -17.35M | -18.09M | -19.15M | -27.79M |
| Investing Cash Flow | - | 0 | -16.01M | 11.66M | -37.00M | 2.05M |
| Financing Cash Flow | 15.06M | 41.09M | -204.77K | 8.41M | 103.48M | 108.46M |
| Capital Expenditure | - | -0 | -243.25K | -14.24K | -0 | -13.40K |
| Free Cash Flow | - | -14.30M | -17.59M | -18.10M | -19.15M | -27.80M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | -403.5% | - | - | - | - | - |
| Net Margin % | -407.7% | - | - | - | - | - |
| ROE % | -29.1% | - | -85.8% | -173.3% | -29.0% | -27.9% |
| ROCE % | -28.0% | - | -85.3% | -181.5% | -30.1% | -30.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sands Capital Alternatives, LLC | 9.33% | 13.02M | $25.65M |
| 2 | Soleus Capital Management, L.P. | 7.79% | 10.88M | $21.42M |
| 3 | Trails Edge Capital Partners, LP | 6.49% | 9.05M | $17.83M |
| 4 | Fairmount Funds Management LLC | 6.18% | 8.62M | $16.99M |
| 5 | Blackrock Inc. | 5.57% | 7.77M | $15.30M |
| 6 | Adar1 Capital Management, LLC | 5.29% | 7.39M | $14.55M |
| 7 | Blackstone Inc | 4.26% | 5.94M | $11.70M |
| 8 | Siren, L.L.C. | 4.19% | 5.85M | $11.52M |
| 9 | Commodore Capital Lp | 3.87% | 5.40M | $10.63M |
| 10 | Vanguard Capital Management LLC | 3.54% | 4.94M | $9.72M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IKT
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Stock Has Consensus Target Price of $4.75 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPQ3MydWpUUmIwRHd2MjhVNC05YVdfcWROeElVZ3lBY284aWRqUW1QclY4TDRCb2MxR0pKbVVyTzhiYkVPLVJCaU4zcmZjLWc3c0RmRGQ2czFZU2VzY2FpTGJlUlItNTcyX19ERnZwQks4Y3RjSlVWM2M3dFozaUNpMEl3c0M1M3MzV2dEbz…
Inhibikase Appoints Scott Wasserman to Board of Directors - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxOWGZsZnp3LWNocmI5V0gzendwQVRzbzNCQjlZMzZ5QzJkUzZRYmFBU3NMQlBvVnlnVmQxMmlPeFFDN2NXMjFPckpaaXhQcUNoZnU3V2RHVmxmTkZXS2NKeHpWY0Z5RXNra3pvY0xaaHhnLVlEOTA5WUhsbFZaZThzY3k4UTktQlZhZWt0M1…
A cardiologist with more than two decades helping develop medicines joins Inhibikase’s board. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQeTVEV3cyV2Yzc2hKX2VqRXBsNkFjanItNG1aTEpOaHByU3lZQnhlZTllVmVtVW5SNWdwQm5yRjhCdmY1RWE1eDdtQS1WZHJ2VzVNZWNwUl9Ldzhocl9XLWFQempxQk1oMnZXZEJscUxEdEpRVHhPbGZ6U2p4MU9RekZZQTFTbFFXVkR1bW…
IKT Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE5iS051Z0xjdkFCdElEdUJId3R2OHpRVmdkRzV4NzZxX3BnRHgwNzNrdEkycTdZRWsxVW1ZT0NJazdJVTNfRVBTMmxzUlVEMlB4b2pHZjJsaVZyU0VzQzlMQmpRS3JDZEwzclBYZTZuVnJOWnR3UjJMeQ?oc=5" target="_blank">IKT F…
IKT Initiated Coverage by Chardan Capital -- Rating Set to Neutr - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPN0l4MXFfTEV3c3NaYjVxYl8xTzY5cmJOMGdZdTJTNkNOMFZwajhKQjJsZWFfbE94YllnOGNGX0F5c3RIOVNEZm1RdUdDM1NfdVh3RGhVZ3RMT1EwUHV1aXBlU1dBdW5oSUxhMjdsclFXYUphNW93aHV4ZjF1SGtpck9zRllod3Jvb1pZbj…
IKT 8-K & SEC Filings - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE15YjZGVDV6QVZXT25ERnhRazhDa2Z3VEkyLVFCQUF1YVlNZWpFNnY2T0NvRUtkbGFJS09nNy1YMi1YS28xeUN3dTJVb0lvS2EtdWFHREk4dFZSeTFENE1uSlhmSC1FMkRITU5XUzNoMEU1bXhxSjl1VVkwM1o?oc=5" target="_blank">…
IKT — Frequently Asked Questions
What is the current share price of Inhibikase Therapeutics, Inc. (IKT)?
As of 2026-10-23 16:27 PDT, Inhibikase Therapeutics, Inc. (IKT) trades at $1.59 on NasdaqCM. Its 52-week range is $1.41 to $2.52.
What is the market capitalisation of IKT?
Inhibikase Therapeutics, Inc. (IKT) has a market capitalisation of $221.86M on NasdaqCM.
What is the P/E ratio of IKT?
IKT trades at a trailing price-to-earnings (P/E) ratio of -3.61. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 2.62.
What is the return on equity (ROE) of IKT?
IKT has a return on equity (ROE) of -51.96%. Its return on capital employed (ROCE) is -30.85%.
Is IKT a good stock to buy?
This page provides a data-driven analysis of Inhibikase Therapeutics, Inc. (IKT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.